Brind.

JPMorgan Chase is facing setbacks regarding its pipeline investments concerning Amphastar Pharmaceuticals.

1 report, 1 independent Updated Jul 10

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

JPMorgan Chase Amphastar Pharmaceuticals

Keep exploring

The entities involved

JPMorgan Chase
American multinational banking and financial services holding company
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
- JPMorgan Chase began analyst coverage with an Overweight rating on Alkami Technology, Inc. on June 26, 2025.Mon 02:31
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company

Nothing else this week.

Related events

JPMorgan Chase, Mayer Brown, Candid, and FICO are discussing financial industry regulation and trends in the context of market services.Jul 21

Coverage

Newest first; wire copies grouped

Jul 10Insider MonkeyJPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the 13 Cheap Healthcare Stocks with Huge